UCB report is cagey about interim results
Belgian drugmaker UCB has released its interim report for the first quarter of 2008, but witheld any specific figures or full-year guidance pending analysis of its recall of Parkinson's treatment Neupro (rotigotine transdermal patch; Marketletter March 31).
The firm noted that net income and revenue during the quarter were in-line with expectations and "decreased by only a single-digit percentage" versus the like period the year before, yet the report did not include any indication as to what the figures were. The firm stated that "the full effect [of the recall] on UCB's business is not known," as such the full-year guidance for 2008 remains "under review." The company expects to offer an update on the situation in its half-year report on August 1.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze